Trials / Completed
CompletedNCT04749368
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Brii Biosciences Limited · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BRII-835 (VIR-2218) | BRII-835 (VIR-2218) will be given by subcutaneous injection |
| BIOLOGICAL | BRII-179 (VBI-2601) with IFN-α | BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection |
| BIOLOGICAL | BRII-179 (VBI-2601) | BRII-179 (VBI-2601) will be administered by intramuscular injection |
Timeline
- Start date
- 2021-04-12
- Primary completion
- 2023-07-04
- Completion
- 2023-07-04
- First posted
- 2021-02-11
- Last updated
- 2024-06-18
Locations
28 sites across 6 countries: Australia, China, New Zealand, Singapore, South Korea, Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04749368. Inclusion in this directory is not an endorsement.